Stock 8622 HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Huakang Biomedical Holdings Company Limited

Equities

8622

KYG4644W1069

Medical Equipment, Supplies & Distribution

Delayed Hong Kong S.E.
Other stock markets
 04:08:16 2024-05-02 EDT 		5-day change 1st Jan Change
0.098 HKD 0.00% Intraday chart for Huakang Biomedical Holdings Company Limited -3.92% -8.41%
03-28 Huakang Biomedical Holdings Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-25 Huakang Biomedical Holdings Company Limited Provides Group Earnings Guidance for the Year Ended 31 December 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022
Capitalization 1 144 48.26 36.02 80.83 67.72
Enterprise Value (EV) 1 89.21 1.077 -3.279 46.41 36.29
P/E ratio -240 x -170 x -3.1 x -19.2 x -21.5 x
Yield - - - - -
Capitalization / Revenue 5.02 x 1.89 x 1.64 x 3.09 x 2.67 x
EV / Revenue 3.11 x 0.04 x -0.15 x 1.78 x 1.43 x
EV / EBITDA 8.7 x 0.7 x 0.51 x -16.4 x -12.4 x
EV / FCF 13.1 x -0.21 x 1.62 x -16.1 x -12.7 x
FCF Yield 7.65% -482% 61.6% -6.2% -7.87%
Price to Book 2.03 x 0.68 x 0.58 x 1.4 x 1.2 x
Nbr of stocks (in thousands) 400,000 400,000 400,000 400,000 414,472
Reference price 2 0.3600 0.1206 0.0901 0.2021 0.1634
Announcement Date 19-03-28 20-03-31 21-03-24 22-03-30 23-03-24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 26.54 28.68 25.47 21.97 26.13 25.33
EBITDA 1 12.13 10.26 1.532 -6.449 -2.822 -2.918
EBIT 1 11.06 8.918 -0.077 -8.297 -4.317 -4.696
Operating Margin 41.66% 31.1% -0.3% -37.77% -16.52% -18.54%
Earnings before Tax (EBT) 1 -0.247 1.242 0.658 -11.37 -3.903 -3.007
Net income 1 -1.952 -0.459 -0.284 -11.63 -4.22 -3.075
Net margin -7.35% -1.6% -1.11% -52.93% -16.15% -12.14%
EPS 2 -0.007501 -0.001503 -0.000710 -0.0291 -0.0106 -0.007599
Free Cash Flow 1 5.416 6.829 -5.197 -2.02 -2.878 -2.857
FCF margin 20.41% 23.81% -20.4% -9.2% -11.01% -11.28%
FCF Conversion (EBITDA) 44.66% 66.57% - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 18-11-29 19-03-28 20-03-31 21-03-24 22-03-30 23-03-24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 19.7 54.8 47.2 39.3 34.4 31.4
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 5.42 6.83 -5.2 -2.02 -2.88 -2.86
ROE (net income / shareholders' equity) -6.34% -0.85% -0.4% -17.5% -7.06% -5.38%
ROA (Net income/ Total Assets) 16.1% 8.45% -0.06% -6.85% -3.86% -4.4%
Assets 1 -12.13 -5.429 478.9 169.7 109.3 69.91
Book Value Per Share 2 0.1200 0.1800 0.1800 0.1500 0.1400 0.1400
Cash Flow per Share 2 0.0700 0.1400 0.1200 0.1000 0.0900 0.0800
Capex 1 4.69 1.77 1.84 1.74 1.95 0.65
Capex / Sales 17.65% 6.18% 7.23% 7.93% 7.47% 2.56%
Announcement Date 18-11-29 19-03-28 20-03-31 21-03-24 22-03-30 23-03-24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

1st Jan change Capi.
HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED Stock Huakang Biomedical Holdings Company Limited
-8.41% 6.27M
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-9.59% 7.67B
DIASORIN S.P.A. Stock DiaSorin S.p.A.
-1.20% 5.41B
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+26.10% 4.62B
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
+0.02% 4.57B
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-53.02% 3.22B
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+6.42% 2.59B
VITROLIFE AB Stock Vitrolife AB
-14.95% 2.05B
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-8.29% 1.79B
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
+0.42% 1.76B
Diagnostic & Testing Substances
  1. Stock Market
  2. Equities
  3. 8622 Stock
  4. Financials Huakang Biomedical Holdings Company Limited